Moderna Inc. said on Wednesday that a new version of its coronavirus vaccine produced a better immune response against omicron Compared to the original shot, as the drugmaker pursues boosters against a surge in infections during the fall season.
The vaccine, which was given as the fourth dose in a trial that enrolled more than 800 people, increased the virus neutralizing antibodies against Omicron by eightfold.
The company said it plans to submit data on the vaccine, which targets Omicron as well as the original coronavirus strain, to regulators in the coming weeks and that the doses could be available to consumers by late summer, its shares said. can send up to 3%.
Modern President Stephen Hoe Said that the company was in touch with U.S. Food and Drug Administration (FDA) and other regulators on the study’s design, which should make filing an easier process.
“We expect those to be relatively straightforward discussions and presentations,” he said.
It is not known whether countries, including the United States, will adopt the same annual decline booster as the flu market.
“The data looks quite comforting and reassuring,” Dr. William Schaffneran infectious disease specialist Vanderbilt University Medical Center,
He said that while he expects the FDA to authorize the vaccine, it is not known whether U.S. Centers for Disease Control and Prevention Will recommend the shot for all adults or for a subset of the population, such as older people.
chief executive Stephen Bansal said the company is accelerating construction of the new booster with the aim of being ready to ship in early August.
In the study, which did not measure the effectiveness of the vaccine, the booster vaccine generated more antibodies against alpha, beta, gamma, delta variants than the original shot.
The vaccine, which was given as the fourth dose in a trial that enrolled more than 800 people, increased the virus neutralizing antibodies against Omicron by eightfold.
The company said it plans to submit data on the vaccine, which targets Omicron as well as the original coronavirus strain, to regulators in the coming weeks and that the doses could be available to consumers by late summer, its shares said. can send up to 3%.
Modern President Stephen Hoe Said that the company was in touch with U.S. Food and Drug Administration (FDA) and other regulators on the study’s design, which should make filing an easier process.
“We expect those to be relatively straightforward discussions and presentations,” he said.
It is not known whether countries, including the United States, will adopt the same annual decline booster as the flu market.
“The data looks quite comforting and reassuring,” Dr. William Schaffneran infectious disease specialist Vanderbilt University Medical Center,
He said that while he expects the FDA to authorize the vaccine, it is not known whether U.S. Centers for Disease Control and Prevention Will recommend the shot for all adults or for a subset of the population, such as older people.
chief executive Stephen Bansal said the company is accelerating construction of the new booster with the aim of being ready to ship in early August.
In the study, which did not measure the effectiveness of the vaccine, the booster vaccine generated more antibodies against alpha, beta, gamma, delta variants than the original shot.